CXCR1 and neoplasm: Several groups have sought to target this by armoring CAR T-cells with CXCR1 or CXCR2, both of which are CXCL8 receptors, with the aim of exploiting tumor CXCL8 expression to improve CAR T-cell migration to tumors (12, 176, 177).